Exelixis registers Phase 2 trial of zanzalintinib plus pembrolizumab in squamous NSCLC maintenance
Exelixis has registered "STELLAR-202," a single-arm Phase 2 study testing zanzalintinib with pembrolizumab as first-line maintenance in metastatic squamous NSCLC.
Exelixis had one registry item this week, a newly posted trial record.
- Exelixis is sponsoring a Phase 2, single-arm trial (NCT07845786, "STELLAR-202") testing zanzalintinib in combination with pembrolizumab as first-line maintenance therapy in participants with metastatic squamous NSCLC.1 The study is listed as recruiting, with an estimated enrollment of 60 participants.1 Participants first receive induction therapy, and those with complete response, partial response, or stable disease will move to maintenance with zanzalintinib and pembrolizumab via intravenous infusion.1 The primary outcome measure is Progression-Free Survival (PFS) at 6 Months (PFS-6) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as Assessed by Investigator.1 The record lists one site in the United States, at Nebraska Cancer Specialists - Midwest Cancer Center - Legacy in Omaha, Nebraska.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.